ABCB1 and SLCO1B1 gene polymorphisms predict methotrexate-resistant for low-risk gestational trophoblastic neoplasia.

Abstract

Aim: The aim of this study was to explore the effects of ABCB1 and SLCO1B1 gene polymorphisms and the methotrexate (MTX) treatment response in patients with low-risk gestational trophoblastic neoplasia (GTN). Materials & methods: Low-risk GTN patients who received MTX as a first-line single agent were enrolled. DNA was extracted from peripheral blood samples from 18 patients and assessed for ABCB1 C3435T and SLCO1B1 T521C. Results:ABCB1 C3435T and SLCO1B1 T521C polymorphisms were not associated with the MTX response or toxicity in Thai patients Conclusion: The selected ABCB1 and SLCO1B1 polymorphism do not predict the risk of MTX resistance in low-risk GTN.

• Authors: Manasawee Srisuttayasathien, Nutthada Areepium, Ruangsak Lertkhachonsuk
• Journal: Personalized medicine (Per Med) Vol. 18 Issue 2 Pg. 107-114 (03 2021) ISSN: 1744-828X [Electronic] England
• PMID: 33565324 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• ABCB1 protein, human
• ATP Binding Cassette Transporter, Subfamily B
• Antimetabolites, Antineoplastic
• Liver-Specific Organic Anion Transporter 1
• SLCO1B1 protein, human
• Methotrexate

Topics

• ATP Binding Cassette Transporter, Subfamily B (genetics)
• Adult
• Antimetabolites, Antineoplastic (therapeutic use)
• Drug Resistance, Neoplasm (genetics)
• Female
• Gestational Trophoblastic Disease (drug therapy, genetics)
• Humans
• Liver-Specific Organic Anion Transporter 1 (genetics)
• Methotrexate (therapeutic use)
• Polymorphism, Genetic
• Pregnancy
• Risk Factors
• Thailand